These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15585924)

  • 21. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
    Bertholet S; Iggo R; Corradin G
    Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition of interspecies hybrid class I histocompatibility antigens by antigen-specific cytolytic T lymphocytes.
    Maziarz R; Allen H; Strominger JL; Flavell R; Biro PA; Burakoff SJ
    Proc Natl Acad Sci U S A; 1985 Sep; 82(18):6276-80. PubMed ID: 3875858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
    Mangino G; Grazia Capri M; Barnaba V; Alberti S
    Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
    Kourilsky P; Jaulin C; Ley V
    Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth-dependent variation of major histocompatibility complex (MHC) restriction and expression of Ly-2 and CD3/alpha/beta T cell receptor in cloned cytotoxic T cells.
    Weltzien HU; Kempkes B; Studer R; Melchers I; Eichmann K
    Eur J Immunol; 1988 Mar; 18(3):431-7. PubMed ID: 2965649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A third class I major histocompatibility complex antigen encoded by a gene in the D region of the H-2d haplotype recognized by cytotoxic T lymphocytes.
    Mann DW; Forman J
    Immunogenetics; 1988; 28(1):38-45. PubMed ID: 3259946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro.
    Gagliardi MC; De Petrillo G; Salemi S; Boffa L; Longobardi MG; Dellabona P; Casorati G; Tanigaki N; Harris R; Lanzavecchia A
    Int Immunol; 1995 Nov; 7(11):1741-52. PubMed ID: 8580072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire.
    Obst R; Münz C; Stevanović S; Rammensee HG
    Eur J Immunol; 1998 Aug; 28(8):2432-43. PubMed ID: 9710221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell tolerance induced in nude mice grafted with thymic epithelium.
    Robinson JH; Chapman CJ; Loveland BE; Jordan RK
    Immunology; 1992 Feb; 75(2):318-24. PubMed ID: 1551693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
    Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
    Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
    Jäger D; Jäger E; Knuth A
    J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
    Zügel U; Schoel B; Kaufmann SH
    J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incomplete tolerance to the tumour-associated antigen MDM2.
    Ramírez F; Ghani Y; Stauss H
    Int Immunol; 2004 Feb; 16(2):327-34. PubMed ID: 14734618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.
    Morandi F; Chiesa S; Bocca P; Millo E; Salis A; Solari M; Pistoia V; Prigione I
    Neoplasia; 2006 Oct; 8(10):833-42. PubMed ID: 17032500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
    Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
    Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
    J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.